• I-BET151 (GSK1210151A): Practical Guidance for BET Inhibitio

  2026-04-25

  I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor designed for precise modulation of BRD2, BRD3, and BRD4 in cancer biology workflows, notably apoptosis and cell cycle arrest assays. It is intended solely for preclinical research use and should not be applied in diagnostic or clinical contexts. Reliable performance depends on adherence to solubility and handling recommendations.

• Dissecting Cancer Drug Responses: In Vitro Methods and BET I

  2026-04-24

  Schwartz's dissertation critically advances in vitro evaluation of anti-cancer drug responses by distinguishing between relative and fractional viability, revealing nuanced drug effects on proliferation versus cell death. This refined approach enables more precise characterization of agents like BET bromodomain inhibitors, informing translational research and drug development.

• DiscoveryProbe Bioactive Compound Library Plus: Applied Work

  2026-04-24

  The DiscoveryProbe Bioactive Compound Library Plus empowers researchers with a ready-to-use, 5,072-compound collection for high-throughput ligand screening and pathway analysis. Its rigorous validation and diverse pathway coverage streamline experimental design, troubleshooting, and translational applications across apoptosis, cancer, and immunology research.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Evidence &

  2026-04-23

  The JC-1 Mitochondrial Membrane Potential Assay Kit provides sensitive, ratiometric detection of mitochondrial membrane potential (ΔΨm) for apoptosis and mitochondrial function analysis. Its robust red/green fluorescence readout enables quantitative monitoring of mitochondrial health in research applications, with validated benchmarks for reproducibility and workflow integration.

• Prostaglandin E2 (PGE2): Molecular Precision in Cardiovascul

  2026-04-23

  Explore the multifaceted roles of Prostaglandin E2 (PGE2) in cardiovascular and immune research. This article delivers a deep-dive into PGE2's receptor pharmacology, its cross-talk with inflammation and mucosal protection, and practical assay insights not covered in standard workflows.

• XAV939 Inhibition of Wnt/β-catenin Does Not Alleviate Coliti

  2026-04-22

  This study rigorously evaluates the impact of XAV939-mediated Wnt/β-catenin pathway inhibition on inflammation in a dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) mouse model. Despite effective suppression of Wnt/β-catenin signaling and SOX9, XAV939 did not improve epithelial inflammation or restore absorptive cell differentiation, challenging assumptions about this pathway’s centrality in UC pathogenesis.

• Gepotidacin (BA1220): Reliable Solutions for Antibacterial A

  2026-04-22

  This scenario-driven guide addresses common laboratory challenges in antibacterial research and cytotoxicity assays, focusing on Gepotidacin (SKU BA1220) as a validated, reproducible solution. Backed by peer-reviewed literature and quantitative data, the article demonstrates how Gepotidacin advances assay sensitivity and experimental reliability for researchers targeting bacterial topoisomerase pathways.

• EZ Cap™ EGFP mRNA (5-moUTP): High-Efficiency Reporter mRNA

  2026-04-21

  EZ Cap EGFP mRNA 5-moUTP is a synthetic, capped mRNA engineered for robust expression of enhanced green fluorescent protein in mammalian systems. It combines a Cap 1 structure, 5-methoxyuridine modification, and an optimized poly(A) tail to maximize translation efficiency, stability, and immune evasion for gene expression studies.

• Streptozotocin: Precision Tools for Translational Diabetes M

  2026-04-21

  Explore the mechanistic foundations, protocol optimization, and strategic translational impact of Streptozotocin (STZ) for diabetes and neuropathy research. This thought-leadership piece integrates new mechanistic insights, evidence-backed protocol guidance, and a critical bridge to emerging neuroinflammatory paradigms, positioning APExBIO's Streptozotocin as an essential research tool.

• Strategic Immunofluorescence: Cy3 Antibody in Biomarker Disc

  2026-04-20

  This thought-leadership article explores how the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody from APExBIO catalyzes breakthroughs in translational biomarker discovery. By connecting mechanistic insights, rigorous validation, and practical guidance, it empowers researchers to elevate immunofluorescence assay sensitivity for early disease monitoring, as exemplified in recent diabetic nephropathy studies.

• Erastin: Ferroptosis Inducer for Precision Cancer Research

  2026-04-20

  Erastin is a potent, selective ferroptosis inducer widely used in cancer biology research. Its mechanism—targeting system Xc⁻ and VDAC—enables controlled induction of iron-dependent, non-apoptotic cell death in RAS/BRAF-mutant cells. Robust evidence and protocol clarity make Erastin (APExBIO, SKU B1524) a benchmark reagent for dissecting oxidative cell death pathways.

• Talabostat Mesylate (PT-100): Precision FAP & DPP4 Inhibitio

  2026-04-19

  Talabostat mesylate (PT-100) is redefining preclinical oncology and immunology research by enabling precise, dual inhibition of DPP4 and FAP. This guide translates advanced findings into actionable protocols for tumor microenvironment modulation and T-cell immunity, with proven troubleshooting strategies and data-driven enhancements.

• Protease Inhibitors Suppress Light-Induced Stomatal Opening

  2026-04-18

  This study demonstrates that specific protease inhibitors can block blue light-induced stomatal opening by interfering with plasma membrane H+-ATPase activity in Commelina benghalensis. The findings reveal a previously underexplored regulatory layer in guard cell signaling, offering new directions for plant physiology and chemical biology research.

• Charge-Reversed Exosomes Enable mRNA Delivery to Cartilage i

  2026-04-17

  This study introduces engineered charge-reversed exosomes as a non-viral platform for targeted mRNA delivery to cartilage, overcoming the electrostatic barrier of glycosaminoglycan-rich tissues in osteoarthritis. The approach achieves robust intra-cartilage gene expression and demonstrates translational potential for mRNA-based therapies, as validated by successful enhanced green fluorescent protein (EGFP) mRNA delivery and expression in deep cartilage layers.

• Pleiotrophin’s Role in BPH: Cell Dynamics, Contraction, and

  2026-04-16

  Liu et al. (2025) provide compelling evidence that pleiotrophin (PTN) is a central regulator of cell proliferation, smooth muscle contraction, and fibrotic remodeling in benign prostatic hyperplasia (BPH). By dissecting PTN’s mechanistic contribution using integrative human, animal, and cellular models, the study identifies PTN as a promising therapeutic target in BPH and clarifies the signaling axes involved in prostatic hyperplasia.

16156 records 1/1078 page Next 12345 下5页 Last page